Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Introduces TruSeq® Stranded mRNA and Total RNA Sample Preparation Kits

Published: Wednesday, September 19, 2012
Last Updated: Wednesday, September 19, 2012
Bookmark and Share
Delivers superior data quality for challenging samples, unprecedented view of the transcriptome.

Illumina has introduced TruSeq Stranded mRNA and Total RNA Sample Preparation Kits for RNA sequencing.

The new reagent kits enable researchers to quickly and easily conduct gene expression studies that provide a complete view of the transcriptome, even from low-quality RNA samples, such as formalin-fixed, paraffin-embedded (FFPE) samples.

The Total RNA Sample Preparation Kit efficiently removes ribosomal RNA and other high abundance transcripts using Epicentre's proven Ribo-Zero™ ribosomal RNA reduction chemistry, with an improved workflow optimized for high-throughput studies.

The resulting combination of high-quality ribosomal removal and sample preparation chemistries into a single, streamlined solution provides an exciting new opportunity for researchers to conduct highly-accurate gene expression studies.

"TruSeq Stranded mRNA and Total RNA Sample Preparation Kits offer powerful, high-throughput, and easy-to-use reagent solutions suited to a broad range of study designs, including those that use challenging but important FFPE samples," said Christian Henry, Senior Vice President and General Manager of Illumina's Genomic Solutions Business.

Henry continued, "These types of samples are a rich source of information on changes in gene expression and regulation associated with cancer and a wide range of other diseases."

The TruSeq Stranded RNA Sample Preparation Kits are available in multiple configurations to suit a wide range of study design needs, with offerings for both mRNA-focused and whole-transcriptome analysis, as well as for both small and large sample sizes.

Configurations compatible with human, mouse and rat samples are currently available, with additional offerings planned later this year for plant samples and for the effective removal of globin transcripts from blood samples.

"Illumina's new RNA sequencing kits allow researchers to quickly and robustly analyze nearly every aspect of the transcriptome and will certainly be a powerful new tool in unraveling the complexities of gene regulation," said Brenton Graveley, professor at University of Connecticut Health Centre and researcher in the modENCODE Project.

Graveley continued, "We were able to reliably detect expression changes in coding as well as non-coding RNA species, for which important regulatory roles impacting a rapidly broadening array of phenotypes continue to be discovered."

The TruSeq Stranded mRNA and Total RNA Sample Preparation Kits are the newest additions to the TruSeq line of sample prep solutions, which are designed to further advance data quality, ease-of-use, and the cost effectiveness of sequencing. Additional benefits of TruSeq Stranded mRNA and Total RNA Sample Preparation Kits include:

•An improved workflow, requiring less hands-on time while delivering the same high standard of performance and affordability as Illumina's current TruSeq products.
•High strand specificity and uniform coverage in a comprehensive end-to-end solution.
•Availability in multiple configurations, including 48-sample low-throughput kits containing 12 of 24 total available indexes, and 96-sample high-throughput kits. Additionally, the company recently introduced TruSeq DNA HT Sample Preparation Kits, which contain 96 unique index pairs pre-loaded into 96-well plates.

TruSeq Stranded mRNA and Total RNA Sample Preparation Kits are now shipping.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Files Patent Infringement Suit in the UK Against Premaitha Health
Suit is filed for Infringement of NIPT Patents.
Monday, March 16, 2015
Illumina Revenues Jump 35 Percent
Company’s Third Quarter 2014 Results Announced.
Tuesday, October 21, 2014
Illumina's HiSeq X Ten Sequencing Technology for Population Studies
Next-generation sequencing technologies to be implemented at new High-Throughput Genomics Center for the MENA region.
Tuesday, July 22, 2014
Novogene Acquires an Illumina HiSeq X Ten Sequencing System
First-in-China deal Iincreases Novogene's investment in Illumina's Next-Generation Sequencing technology.
Thursday, February 13, 2014
Illumina Announces Recipients of Agricultural Greater Good Initiative Grants
Expanded program focuses on improving food security and furthering agricultural sustainability.
Wednesday, January 16, 2013
Illumina Awarded FDA Contract for NGS Technology to Identify Foodborne Pathogens
Agency selects MiSeq® system for program to explore NGS as mechanism to enhance food safety.
Wednesday, September 19, 2012
The Broad Institute Joins the Illumina Genome Network
Partnership expands the network’s capabilities to enable sequencing of previously inaccessible samples.
Tuesday, June 05, 2012
Cold Spring Harbor Laboratory Joins the Illumina Genome Network
Partnership expands access to large-scale whole genome sequencing.
Monday, May 28, 2012
Illumina Comments on Roche’s Unsolicited Tender Offer Extension
Roche to acquire all outstanding shares of Illumina for $44.50 in cash per common share.
Monday, February 27, 2012
Illumina's Board Unanimously Rejects Roche's Unsolicited Tender Offer
Urges stockholders not to tender their shares, company considers offer inadequate.
Wednesday, February 08, 2012
BCCA Joins the Illumina Genome Network
Network expansion making affordable, high quality whole human genome sequencing services accessible world-wide.
Friday, January 20, 2012
Illumina Appoints Marc Stapley as Senior Vice President and CFO
Stapley brings multi-national experience in high-growth and mature industries.
Thursday, January 05, 2012
Illumina and University of Oxford to Sequence 500 Whole Human Genomes for Rare Disease Research
Opportunity to bring personalized medicine to the forefront of healthcare.
Tuesday, January 03, 2012
Illumina Reports Financial Results for Second Quarter 2011
Revenue of $287.5 million, a 36% increase over the $212.0 million reported in the second quarter of 2010.
Wednesday, July 27, 2011
University of Washington Department of Genome Sciences Joins Illumina Genome Network
Network makes affordable, high-quality whole human genome sequencing services more accessible to life sciences researchers.
Friday, July 01, 2011
Scientific News
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Discovering the First Farmers
Genetic analyses reveal a collection of highly distinct groups in the Near East and Europe at the dawn of agriculture.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!